2025.04.18
Cell therapies, including CAR - T therapies and stem cell treatments, have made extraordinary progress, significantly transforming modern medicine. There are over 18 FDA - approved cell and gene therapies globally, and 11 of them require cryopreservation. So, optimizing cell viability and functionality during the freezing process has become super crucial. Commercial cryopreservation media play a key role in protecting cellular integrity, but there are still some challenges.
Most FDA - approved cell therapies, such as Yescarta®, Kymriah®, and Abecma®, rely on traditional cryoprotectants like dimethyl sulfoxide (DMSO). Commercial media like CryoStor® CS10 (with 10% DMSO) and CS5 (with 5% DMSO) are widely used because they're effective in maintaining cell viability during freezing.
To meet the demand for innovation, Kryogene™ Cell Freezing Media - CGT by Kryogene redefines the excellence of cryopreservation. This solution, specially designed for cell and gene therapies (CGTs), is serum - free, protein - free, and animal - component - free. It incorporates pre - formulated DMSO into an optimized, ready - to - use formula. Its main advantages are as follows:
With ultra - low endotoxin levels (<0.5 EU/mL) and compliance with cGMP manufacturing processes, it ensures regulatory compliance and minimizes contamination risks. This makes Kryogene™ a reliable choice for applications where sterility and safety are of utmost importance.
Kryogene™ has been validated across various cell types, including CAR - T cells, natural killer (NK) cells, mesenchymal stem cells (MSCs), and tumor - infiltrating lymphocytes (TILs). It achieves a post - thaw viability of over 90%, equaling or even surpassing the performance of world - renowned and top - tier cryopreservation media in clinical - grade cell recovery and functionality testing. It consistently delivers high - quality results, ensuring that cells can still maintain their functions after thawing.
The pre - cooled media enables a rapid and simplified protocol (for example, a cooling rate of - 1°C per minute) without affecting high - density cell storage (up to 5×10⁷ cells/mL). This not only saves time but also allows for more efficient handling of cells during the cryopreservation process.
Independent studies show that Kryogene™ is on a par with leading global brands in maintaining key indicators (such as CD34+ stem cell expansion and CAR - T cell persistence). For instance, donor - derived NK cells preserved with Kryogene™ retain over 85% cytotoxicity against K562 targets, outperforming traditional media in long - term stability. It offers consistent and reliable performance, making it trustworthy for both research and clinical applications.
As cell therapies continue to push the boundaries of medicine, Kryogene™ Cell Freezing Media - CGT provides a safer and more reliable preservation standard. Trusted by clinical and research pioneers, it bridges the gap between efficacy and safety, laying the foundation for future breakthroughs.
Unleash your potential with Kryogene™—where innovation meets precision in preservation.
Learn more at https://www.milecell-bio.com/.
